User login
Key clinical point: Cisplatin and oxaliplatin are both suitable as a part of the systemic therapy for resectable gastric cancer.
Major finding: Patients receiving epirubicin+cisplatin+capecitabine (ECX) and those receiving epirubicin+oxaliplatin+capecitabine (EOX) had comparable 5-year overall survival (42% vs 47%; P = .303), preoperative (67% vs 60%; P = .105) and postoperative (60% vs 51%; P = .266) severe (grades 3-5) toxicity, and complete or near-complete pathological response (21% vs 15%; P = .126) rates.
Study details: This post hoc analysis included 781 adult patients with resectable gastric cancer from the CRITICS trial who received preoperative ECX (n = 632) or EOX (n = 149), of which 636 and 233 received potentially curative surgery and postoperative chemotherapy, respectively.
Disclosures: The CRITICS trial was sponsored by the Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche; this analysis required no additional funding. The authors declared no conflicts of interest.
Source: Slagter AE et al. Triplet chemotherapy with cisplatin versus oxaliplatin in the CRITICS trial: Treatment compliance, toxicity, outcomes and quality of life in patients with resectable gastric cancer. Cancers (Basel). 2022;14(12):2963 (Jun 15). Doi: 10.3390/cancers14122963
Key clinical point: Cisplatin and oxaliplatin are both suitable as a part of the systemic therapy for resectable gastric cancer.
Major finding: Patients receiving epirubicin+cisplatin+capecitabine (ECX) and those receiving epirubicin+oxaliplatin+capecitabine (EOX) had comparable 5-year overall survival (42% vs 47%; P = .303), preoperative (67% vs 60%; P = .105) and postoperative (60% vs 51%; P = .266) severe (grades 3-5) toxicity, and complete or near-complete pathological response (21% vs 15%; P = .126) rates.
Study details: This post hoc analysis included 781 adult patients with resectable gastric cancer from the CRITICS trial who received preoperative ECX (n = 632) or EOX (n = 149), of which 636 and 233 received potentially curative surgery and postoperative chemotherapy, respectively.
Disclosures: The CRITICS trial was sponsored by the Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche; this analysis required no additional funding. The authors declared no conflicts of interest.
Source: Slagter AE et al. Triplet chemotherapy with cisplatin versus oxaliplatin in the CRITICS trial: Treatment compliance, toxicity, outcomes and quality of life in patients with resectable gastric cancer. Cancers (Basel). 2022;14(12):2963 (Jun 15). Doi: 10.3390/cancers14122963
Key clinical point: Cisplatin and oxaliplatin are both suitable as a part of the systemic therapy for resectable gastric cancer.
Major finding: Patients receiving epirubicin+cisplatin+capecitabine (ECX) and those receiving epirubicin+oxaliplatin+capecitabine (EOX) had comparable 5-year overall survival (42% vs 47%; P = .303), preoperative (67% vs 60%; P = .105) and postoperative (60% vs 51%; P = .266) severe (grades 3-5) toxicity, and complete or near-complete pathological response (21% vs 15%; P = .126) rates.
Study details: This post hoc analysis included 781 adult patients with resectable gastric cancer from the CRITICS trial who received preoperative ECX (n = 632) or EOX (n = 149), of which 636 and 233 received potentially curative surgery and postoperative chemotherapy, respectively.
Disclosures: The CRITICS trial was sponsored by the Dutch Cancer Society, Dutch Colorectal Cancer Group, and Hoffmann-La Roche; this analysis required no additional funding. The authors declared no conflicts of interest.
Source: Slagter AE et al. Triplet chemotherapy with cisplatin versus oxaliplatin in the CRITICS trial: Treatment compliance, toxicity, outcomes and quality of life in patients with resectable gastric cancer. Cancers (Basel). 2022;14(12):2963 (Jun 15). Doi: 10.3390/cancers14122963